Source: BioSpace
05.30.2008
AmpliMed Corporation, a cancer therapeutics company, today announced that data from three clinical trials of Amplimexon(R) in various cancer types will be presented during the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) taking place May 30 to June 3, 2008, at McCormick Place in Chicago. Investigators will present final results from a Phase 1/2 trial of Amplimexon (imexon for injection) in metastatic melanoma, updated data from a Phase 1 trial of Amplimexon in combination with docetaxel (Taxotere) in breast, lung and prostate cancer and updated data from a Phase 1 trial of Amplimexon in combination with gemcitabine (Gemzar(R)) in advanced pancreatic cancer.
Amplimexon, AmpliMed's lead product candidate, is a chemotherapeutic that has demonstrated clinical and preclinical activity against a range of tumors. It has been evaluated in nearly 300 patients and has demonstrated clinical activity both as a monotherapy and in combination with other therapies.
"These presentations at ASCO highlight the applicability of Amplimexon for a wide range of cancer types," said Robert T. Dorr, Ph.D. R. Ph., Chief Executive Officer of AmpliMed.
External Link: Click here for the external article.
